Biopharmaceutical News and Research

RSS

Researchers receive NIH grant to test novel drug therapy for Alzheimer's dementia

Johns Hopkins University researchers have received an estimated $7.5 million National Institutes of Health grant to clinically test what would be the first treatment to prevent or delay the onset of Alzheimer's dementia.

16 Sep 2015

AgeneBio's HOPE4MCI Phase 3 trial receives support from NIH

AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, announced today that its HOPE4MCI Phase 3 clinical trial has received support from the National Institutes of Health.

15 Sep 2015

Aridis' AR-301 granted FDA Fast Track Designation for treatment of pneumonia caused by S. aureus

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration granted Fast Track Designation to AR-301, the Company's fully human anti-Staphylococcal alpha-toxin IgG1 monoclonal antibody (mAb).

11 Sep 2015

Envision inaugurates 10th Annual Conference, honors outstanding achievements in low vision rehabilitation

Envision, the Wichita, Kan.-based not-for-profit organization that supports those who are blind and visually impaired, officially opened its 10th Annual Conference at The Grand Hyatt in downtown Denver this morning with a session honoring outstanding commitment to improving the quality of life of those who are blind and visually impaired and keynote addresses from two individuals representing the great athletic accomplishments those with vision loss can achieve.

11 Sep 2015

BerGenBio honored with Nordic Stars Award for innovation in Nordic life science community

BerGenBio AS ("BerGenBio" or the "Company"), an oncology biopharmaceutical company, today announces that it has been awarded one of this year's Nordic Stars Awards at the Nordic Life Science Days 2015 conference held in Stockholm, Sweden on 9-10 September, 2015.

11 Sep 2015

DelMar presents updated VAL-083 Phase I/II trial data at GBM2015 meeting

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today presented updated clinical data from its Phase I/II study of lead product candidate VAL-083 (dianhydrogalactitol), in patients with refractory glioblastoma multiforme (GBM), at GBM2015: 2nd International Symposium on Clinical and Basic Investigation in Glioblastoma in Toledo, Spain.

10 Sep 2015

CureVac, IAVI team up to advance development, testing of AIDS vaccines

The non-profit International AIDS Vaccine Initiative (IAVI) and biopharmaceutical company CureVac are partnering to accelerate the development of AIDS vaccines, utilizing novel immunogens developed by IAVI and partners, delivered via CureVac's novel messenger RNA (mRNA) technology.

10 Sep 2015

CureVac announces official launch of U.S. operations in Cambridge, MA

CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announced the official launch of its U.S. operations in Cambridge, MA, as the company advances the development of its proprietary mRNA platform technology and multiple, clinical-stage mRNA therapeutics and vaccines.

10 Sep 2015

Inhibiting key protein involved in glucose production may help in treating type 2 diabetes

Some treatments for type 2 diabetes make the body more sensitive to insulin, the hormone that lowers blood sugar. But new research at Washington University School of Medicine in St. Louis suggests a different strategy: slowing the production of glucose in the liver.

4 Sep 2015

Adaptimmune doses first patient in expanded Phase I/II trial of T-cell therapy for synovial sarcoma

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the first patient has been dosed in its expanded Phase I/II trial of its affinity enhanced T-cell receptor therapeutic targeting the NY-ESO-1 cancer antigen in synovial sarcoma patients.

3 Sep 2015

Sanofi terminates option and license agreement for Ardelyx's portfolio of NaP2b inhibitors

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Sanofi notified Ardelyx of its termination of the option and license agreement for Ardelyx's portfolio of NaP2b inhibitors effective September 30, 2015.

2 Sep 2015

Bionomics submission of BNC101 IND for cancer treatment passes FDA review

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today announced that its BNC101 IND submission has passed review by the US Food and Drug Administration (FDA).

31 Aug 2015

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has completed enrollment of the additional subjects, as directed by the Data Review Committee (DRC) earlier this year, into the company's Phase 2 study for SGX942.

31 Aug 2015

Practices for expediting corporate market research approval process for faster insights

Delays in the launch and execution of critical market research projects can slow down the decision-making process, resulting in missed opportunities and increased costs. It is, therefore, absolutely critical for biopharmaceutical companies to develop a tactical approach to expedite the market research approval process for quicker and more meaningful insights.

29 Aug 2015

CytomX announces filing of registration statement for proposed initial public offering of common stock

CytomX Therapeutics, Inc., a biopharmaceutical company developing Probody therapeutics for the treatment of cancer, today announced the filing of a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock.

29 Aug 2015

Breakthrough approach saves patient's eyes and life from flesh-eating disease

The National Necrotizing Fasciitis Foundation today announced that a patient's eyes—and life—were saved by doctors at Vanderbilt University Hospital in Nashville, TN, working with NNFF, NovaBay Pharmaceuticals and Dr. John Crew, director of the Advanced Wound Care Center at Seton Medical Center in Daly City, CA.

27 Aug 2015

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP).

27 Aug 2015

MNX Global Logistics' new Life Sciences Logistics Centre opens in Amsterdam

MNX Global Logistics announces the opening of its dedicated supply chain and logistics facility in Amsterdam, the Netherlands, located just outside of Amsterdam Airport Schiphol. This facility with validated temperature-controlled supply chain capabilities will serve as the operations and warehousing hub for our Life Sciences and Medical Device customers throughout Europe.

25 Aug 2015

HPPI commences enrollment for Phase II(b) SCORING clinical trial for cancer treatment

HedgePath Pharmaceuticals, Inc., a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today enrollment has commenced in its Phase II(b) SCORING (SUBA-Cap Objective Response in Gorlin's) clinical trial.

23 Aug 2015

Berg and University of Miami extend partnership to battle cardiac dysfunction, heart failure

Berg, a Boston-based biopharmaceutical company, and the University of Miami Leonard M. Miller School of Medicine are extending its collaboration to battle cardiac dysfunction and heart failure. According to the American Heart Association, cardiovascular disease is the leading global cause of death, accounting for 17.3 million deaths per year, a number that is expected to grow to more than 23.6 million by 2030.

23 Aug 2015

Biopharmaceutical News and Research

Researchers receive NIH grant to test novel drug therapy for Alzheimer's dementia

AgeneBio's HOPE4MCI Phase 3 trial receives support from NIH

Aridis' AR-301 granted FDA Fast Track Designation for treatment of pneumonia caused by S. aureus

Envision inaugurates 10th Annual Conference, honors outstanding achievements in low vision rehabilitation

BerGenBio honored with Nordic Stars Award for innovation in Nordic life science community

DelMar presents updated VAL-083 Phase I/II trial data at GBM2015 meeting

CureVac, IAVI team up to advance development, testing of AIDS vaccines

CureVac announces official launch of U.S. operations in Cambridge, MA

Inhibiting key protein involved in glucose production may help in treating type 2 diabetes

Adaptimmune doses first patient in expanded Phase I/II trial of T-cell therapy for synovial sarcoma

Sanofi terminates option and license agreement for Ardelyx's portfolio of NaP2b inhibitors

Bionomics submission of BNC101 IND for cancer treatment passes FDA review

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Practices for expediting corporate market research approval process for faster insights

CytomX announces filing of registration statement for proposed initial public offering of common stock

Breakthrough approach saves patient's eyes and life from flesh-eating disease

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

MNX Global Logistics' new Life Sciences Logistics Centre opens in Amsterdam

HPPI commences enrollment for Phase II(b) SCORING clinical trial for cancer treatment

Berg and University of Miami extend partnership to battle cardiac dysfunction, heart failure

Event guide: The 5th mRNA-Based Therapeutics Summit Europe eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News